Pembrolizumab-Induced Lichenoid Dermatitis in a Patient With Metastatic Cancer of Unknown Primary
نویسندگان
چکیده
منابع مشابه
[Metastatic cancer of unknown primary site].
The history, physical examination, radiographic and laboratory studies and histological diagnosis must be completely evaluated to search for the primary tumor. For diagnosis of cervical lymph node metastasis, not only whole body examination but also head and neck examination is important in which quadrascopy (nasopharyngeal, laryngeal and esophageal fiberoscopy and bronchoscopy) must be perform...
متن کاملAcute liver failure caused by pembrolizumab in a patient with pulmonary metastatic liver cancer
RATIONALE Keytruda (pembrolizumab) is an inhibitor of programmed cell death receptor-1 (PD-1), which was approved to treat advanced melanoma and nonsmall cell lung cancer patients who do not respond to other treatment. However, its efficacy and security in the treatment of advanced liver cancer is still under investigation. PATIENT CONCERNS A 60-year-old man was diagnosed with pulmonary metas...
متن کاملprevalence of atopic dermatitis in children with type 1 diabetes mellitus in southeastern of iran (kerman province): a case-control study
چکیده ندارد.
15 صفحه اولPulmonary Metastatic Choriocarcinoma in a Patient with Ectopic Pregnancy
Gestational trophoblastic tumor (GTT) most commonly follows a molar pregnancy. In fact, it can occur following gestational events such as induced or spontaneous abortion, ectopic pregnancy, and term pregnancy. In this study, we present the case of a patient with ectopic pregnancy who was treated with a single dose of methotrexate (MTX). The maximum titer of beta subunit of human chorionic gonad...
متن کاملLichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy.
Therapies that activate the immune system through blocking the binding of programmed death ligand 1 (PD-L1) present on tumors and PD-1 (programmed death 1) present on activated immune cells are revolutionizing the care for patients with cancer. These therapies work by inhibiting negative regulators of the immune system, thereby decreasing a tumor's ability to evade the immune system. The side e...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cureus
سال: 2021
ISSN: 2168-8184
DOI: 10.7759/cureus.13768